Abstract: A packaged, sealed container system for stable storage of a formulation of an oxygen-sensitive pharmaceutical compound, the packaged, sealed container system comprising a primary container including therein a formulation of an oxygen-sensitive pharmaceutical compound, a secondary outer container comprising a first flexible sheet layer, an opposing second flexible sheet layer, and a seal disposed along a common peripheral edge of the first and second flexible sheet layers, such that the primary container is disposed between and enclosed by the first and second flexible sheet layers of the secondary outer container. An oxygen scavenger is also disposed between and enclosed by the first and second flexible sheet layers of the secondary outer container. The oxygen scavenger is in fluid communication with the contents of the primary container.

Abstract: A packaged, sealed container system for stable storage of a formulation of an oxygen-sensitive pharmaceutical compound, the packaged, sealed container system comprising a primary container including therein a formulation of an oxygen-sensitive pharmaceutical compound, a secondary outer container comprising a first flexible sheet layer, an opposing second flexible sheet layer, and a seal disposed along a common peripheral edge of the first and second flexible sheet layers, such that the primary container is disposed between and enclosed by the first and second flexible sheet layers of the secondary outer container. An oxygen scavenger is also disposed between and enclosed by the first and second flexible sheet layers of the secondary outer container. The oxygen scavenger is in fluid communication with the contents of the primary container.

Abstract: A pharmaceutical composition comprising a solution having an effective amount of famotidine, the solution having a pH in the range of about 4.5 to about 8.0, and a shelf life greater than 30 days.

Abstract: A pharmaceutical composition is provided comprising an unbuffered iso-osmotic aqueous formulation containing an effective amount of ranitidine for the treatment of conditions mediated through histamine H.sub.2 receptors. The formulation has a pH of greater than or equal to 5.0 and less than 6.5 and preferably includes an osmotic adjusting agent chosen from the group consisting of dextrose and sodium chloride.

Abstract: A pharmaceutical composition is provided comprising an unbuffered iso-osmotic aqueous formulation containing an effective amount of ranitidine for the treatment of conditions mediated through histamine H.sub.2 receptors. The formulation has a pH of greater than or equal to 5.0 and less than 6.5 and preferably includes an osmotic adjusting agent chosen from the group consisting of dextrose and sodium chloride.